The feasibility study of 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer

被引：0
|
作者：
Yonemori, Kan [1 ]
Tamura, Kenji [1 ]
Kurihara, Hiroaki [3 ]
Kono, Yuzuru [3 ]
Arai, Yasuaki [3 ]
Wada, Yasuhiro [2 ]
Takahashi, Kazuhiro [3 ]
Hasegawa, Koki [3 ]
Watanabe, Yasuyoshi [3 ]
Fujiwara, Yasuhiro [1 ]
机构：
[1] Natl Canc Ctr Hosp Tokyo, Breast & Med Oncol, Tokyo, Japan
[2] RIKEN, Ctr Mol Imaging Sci, Kobe, Hyogo, Japan
[3] Natl Canc Ctr Hosp Tokyo, Nucl Med, Tokyo, Japan
来源：
JOURNAL OF NUCLEAR MEDICINE | 2012年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1266
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2+breast cancer
    Jarrett, Angela M.
    Hormuth, David A.
    Adhikarla, Vikram
    Sahoo, Prativa
    Abler, Daniel
    Tumyan, Lusine
    Schmolze, Daniel
    Mortimer, Joanne
    Rockne, Russell C.
    Yankeelov, Thomas E.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [22] Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer
    Angela M. Jarrett
    David A. Hormuth
    Vikram Adhikarla
    Prativa Sahoo
    Daniel Abler
    Lusine Tumyan
    Daniel Schmolze
    Joanne Mortimer
    Russell C. Rockne
    Thomas E. Yankeelov
    Scientific Reports, 10
  • [23] Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with 64Cu-DOTA-trastuzumab
    Gang Niu
    Zibo Li
    Qizhen Cao
    Xiaoyuan Chen
    European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36
  • [24] A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT
    Conrad Chan
    Deborah A Scollard
    Kristin McLarty
    Serena Smith
    Raymond M Reilly
    EJNMMI Research, 1
  • [25] A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT
    Chan, Conrad
    Scollard, Deborah A.
    McLarty, Kristin
    Smith, Serena
    Reilly, Raymond M.
    EJNMMI RESEARCH, 2011, 1 : 1 - 11
  • [26] Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
    Dijkers, E. C.
    Munnink, T. H. Oude
    Kosterink, J. G.
    Brouwers, A. H.
    Jager, P. L.
    de Jong, J. R.
    van Dongen, G. A.
    Schroder, C. P.
    Lub-de Hooge, M. N.
    de Vries, E. G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (05) : 586 - 592
  • [27] Trastuzumab Use Modest in Patients With HER2-Positive Breast Cancer
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (05) : 339 - 339
  • [28] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [29] Duration of trastuzumab for HER2-positive breast cancer
    Montemurro, Filippo
    Aglietta, Massimo
    LANCET ONCOLOGY, 2013, 14 (08): : 678 - 679
  • [30] Neratinib after trastuzumab in patients with HER2-positive breast cancer
    Hasegawa, Takahiro
    Uno, Hajime
    Wei, Lee-Jen
    LANCET ONCOLOGY, 2016, 17 (05): : E176 - E176
12345